2026-01-15 - Analysis Report
# Novo Nordisk A/S ADR (NVO) Stock Report
## Company Overview
Novo Nordisk A/S ADR is a healthcare company specializing in developing and manufacturing human vaccines and pharmaceuticals. 

## Performance Analysis
### Return Rate Comparison
- **Review Stock (NVO):** 44.89% cumulative return
- **Comparison Stock (VOO):** 92.89% cumulative return
- **Divergence (max: 120.10, min: -78.50, current: -48.00, relative divergence: 15.40%)**

### Historical Alpha and Beta Analysis
| Year      | CAGR  | MDD  | Alpha | Beta | Market Cap (B) |
|-----------|-------|------|-------|-------|----------------|
| 2016-2018 | 0.0%  | 19.0%| -4.0% | 0.8   | 102.4          |
| 2017-2019 | 37.0% | 13.6%| 20.0% | 0.6   | 128.6          |
| 2018-2020 | 1.0%  | 12.5%| -20.0%| 0.6   | 155.2          |
| 2019-2021 | 58.0% | 13.0%| 15.0% | 0.6   | 248.8          |
| 2020-2022 | 58.0% | 23.2%| 60.0% | 0.6   | 300.7          |
| 2021-2023 | 87.0% | 23.2%| 86.0% | 0.5   | 459.7          |
| 2022-2024 | 18.0% | 40.5%| -1.0% | 0.5   | 382.2          |
| 2023-2025 | -52.0%| 59.7%| -114.0%| 0.7   | 226.1          |

## Recent Stock Price Fluctuations
* **Close:** $58.91
* **5-day SMA:** $58.91
* **20-day SMA:** $53.28
* **60-day SMA:** $50.58
* **Price Change:** $-1.22 (sharp decline)

## Technical Indicators
* **Market Risk Indicator (MRI):** 0.70 (Medium Investment)
* **RSI:** 79.06
* **PPO:** 1.32
* **Hybrid Signal:** Buy (Cash 0%)
* **Recent (20 days) relative divergence change:** 2.70 (+)
* **7-day Rank change:** 0 (0)
* **7-day Dynamic Expected Return change:** 0.00 (0)
* **Expected Return (%):** 287.70%

## News and Events
- A Struggling Stock Vs. A Highly Profitable Strategy (Seeks Alpha)
- Novo Nordisk Soars 19% in a Month: How Should You Play the Stock? (Yahoo Finance)
- 2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 (The Motley Fool)
- Novo Nordisk: NVO Stock To $100? (Forbes)
- Eagle Global Advisors LLC Trims Stake in Novo Nordisk A/S $NVO (MarketBeat)
- Novo Nordisk (NYSE:NVO) Valuation Check After Recent Share Price Strength And Long Term Growth Narrative (Simplywall.st)

## Analyst Opinions
- **Analyst Consensus:**
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 54.78 / 73.35 / 41.60

## Comprehensive Analysis
Based on the analysis of historical performance, recent stock price fluctuations, and technical indicators, Novo Nordisk A/S ADR (NVO) is showing mixed signals. While the stock's cumulative return is lower than the comparison stock (VOO), it is still outperforming in some periods. The historical Alpha and Beta analysis indicates a stable but relatively low-risk profile. The recent price fluctuations are indicating a sharp decline, and the technical indicators suggest a medium-risk investment with a positive expected return. Considering the news and analyst opinions, the overall outlook for NVO is complex and requires further analysis.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.